Alpha Tau Medical to Present Alpha DaRT® Progress at J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- Conference Announcement: Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco, led by CEO Uzi Sofer and CFO Raphi Levy, which is expected to attract significant investor interest.
- Investor Engagement: The event will include one-on-one meetings with institutional investors, aimed at strengthening relationships with potential investors and enhancing the company's visibility in the capital markets, thereby laying the groundwork for future financing.
- Technology Background: Alpha DaRT® is an innovative alpha-radiation cancer therapy focused on treating solid tumors through the intratumoral delivery of radium-224 sources, designed to improve treatment precision and efficacy while minimizing damage to surrounding healthy tissue.
- Company Vision: Founded in 2016, Alpha Tau Medical is dedicated to the research, development, and commercialization of Alpha DaRT®, aiming to carve out a niche in the oncology treatment landscape with its unique therapeutic approach to drive long-term growth.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DRTS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DRTS
Wall Street analysts forecast DRTS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.600
Low
5.00
Averages
7.00
High
9.00
Current: 7.600
Low
5.00
Averages
7.00
High
9.00
About DRTS
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
Continue Reading
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
Continue Reading